Cysts on Kidneys: From Simple Cysts to Polycystic Disease

Most kidney cysts are simple, fluid-filled sacs that form on or within the kidneys, cause no symptoms, and never need treatment. They are remarkably common, showing up in roughly one in ten adults on imaging studies and in a third or more of people over sixty. But the phrase “cysts on kidneys” covers a wide spectrum, from a single harmless bubble found by accident on an ultrasound to the hundreds of expanding cysts that define polycystic kidney disease, a genetic condition that remains one of the leading causes of kidney failure worldwide. Understanding which type you’re dealing with shapes everything that follows.

How Common Simple Kidney Cysts Are

Simple renal cysts are, by a large margin, the most frequent type. A study of health-screening patients found an overall prevalence of about 11%, but the rate climbed steeply with age: roughly 2% of people in their twenties had them, compared with over 35% of those in their seventies and beyond.¹ A separate study tracking patients with microscopic blood in their urine found a similar age-related pattern, with about 4% of people under thirty affected and a third of those over sixty.² Men develop them roughly two to three times more often than women, though the reasons for that gap remain unclear.³

The leading theory for how simple cysts form traces them back to tiny pouches, called diverticula, that bud off the kidney’s distal tubules. Over years, those pouches slowly enlarge, fill with fluid, and eventually become the cysts visible on imaging.⁴ Localized obstruction in part of the kidney appears to speed up that process.⁵ Because the progression is slow and cumulative, simple cysts are essentially a product of aging kidneys, which is why they become so prevalent in older adults.

When Simple Cysts Cause Symptoms

The vast majority of simple cysts sit quietly and are discovered incidentally during an abdominal scan ordered for something else entirely. When they do cause problems, it is usually because the cyst has grown large enough to press on surrounding tissue. In a series of patients treated for symptomatic cysts, the most common complaint was flank or kidney-area pain, followed by a palpable mass, high blood pressure, and blood in the urine.⁶

The blood-pressure connection has attracted research attention. A large population study found that having multiple or large simple cysts was associated with modestly higher systolic and diastolic blood pressure, on the order of a couple of millimeters of mercury.⁷ That is not a dramatic shift for any individual, but it suggests that large cysts may put enough mechanical pressure on renal tissue to trigger the kidney’s own blood-pressure-raising pathways. If you’ve been told you have a simple cyst and your blood pressure is well controlled, the cyst is unlikely to change that picture. If you have several large cysts and newly rising readings, it’s worth mentioning to your doctor.

The Bosniak Classification and Cancer Risk

Not every kidney cyst is simple. When a cyst has internal walls, irregular borders, calcifications, or areas that light up on contrast imaging, radiologists classify it using the Bosniak system, a framework that has been in use for over thirty years to estimate how likely a cystic kidney mass is to be cancerous.⁸ The system sorts cysts into categories I through IV, with higher numbers carrying higher cancer risk.

Category I and II cysts are benign. Category IIF (“F” for follow-up) cysts have slightly more complex features; during surveillance, the vast majority stay stable, and those that do have a cancer rate under 1%. The trouble comes if a IIF cyst changes over time and gets reclassified as III or IV, at which point the cancer rate jumps to around 85%.⁹ Category III cysts carry about a 50% chance of malignancy overall, though one study found that rate as high as 60%, and category IV cysts are malignant roughly 89% of the time.¹⁰ An interesting wrinkle: among Bosniak III lesions, the smaller ones (under four centimeters) were actually more likely to be cancerous than the larger ones.¹¹ Size alone is not a reliable indicator of whether a complex cyst is dangerous.

For imaging, CT remains the standard tool for classifying complex cysts. MRI performs almost as well, with agreement between MRI and CT classifications running above 90% in a prospective comparison. Contrast-enhanced ultrasound, while useful for some purposes, agreed with CT classification only about half the time, which limits its role in the Bosniak system for now.¹²

Treating Symptomatic Simple Cysts

If a simple cyst causes persistent pain or other problems, two main procedures are available. The less invasive option is percutaneous aspiration with sclerotherapy: a needle is inserted through the skin under imaging guidance, the fluid is drained, and a sclerosing agent (usually ethanol) is injected to collapse the cyst walls. The more definitive option is laparoscopic deroofing, a minimally invasive surgery that removes the cyst’s outer wall so it cannot refill.

A systematic review and meta-analysis comparing the two found that laparoscopic deroofing was substantially more effective. Symptomatic relief ranged from 93 to 100% with surgery versus 50 to 95% with aspiration and sclerotherapy. Radiologically, the difference was even starker: the aspiration approach had about eight times the failure rate of the surgical approach.¹³ That said, aspiration is an outpatient procedure done under local anesthesia, while laparoscopic deroofing requires general anesthesia and a hospital stay. For patients who want the least invasive approach or who are poor surgical candidates, aspiration with sclerotherapy remains a reasonable first step, with the understanding that the cyst may recur.¹⁴

Autosomal Dominant Polycystic Kidney Disease

Polycystic kidney disease is an entirely different animal from simple cysts. The autosomal dominant form, ADPKD, is one of the most common inherited conditions, and it accounts for 5 to 10% of all patients with kidney failure.¹⁵ Two genes are responsible for most cases. Mutations in the PKD1 gene cause roughly 80% of cases and tend to be more severe, with kidney failure typically arriving between the ages of 55 and 65. Mutations in PKD2 account for about 15% and follow a slower course, with kidney failure often not developing until the mid-seventies.¹⁶ Several rarer gene variants have also been identified.

At the cellular level, the proteins made by PKD1 and PKD2 normally help regulate calcium signaling in the kidney’s tiny sensory structures called primary cilia. When those proteins are defective, a signaling molecule called cyclic AMP builds up excessively in kidney cells, driving fluid secretion and cyst growth.¹⁷ That understanding led directly to the first approved drug therapy for the condition.

Tracking and Treating ADPKD

For people with ADPKD, total kidney volume (the combined size of both kidneys including all cysts) has become the single most useful marker of how fast the disease is progressing. Multiple studies have confirmed that larger kidneys at any given age predict a faster decline in kidney function. In one study, a twofold increase in total kidney volume roughly doubled the risk of significant kidney function loss over the following years.¹⁸ A height-adjusted kidney volume above 600 milliliters per meter was the threshold that most accurately predicted developing moderate kidney disease within eight years.¹⁹ Because standard blood tests of kidney function can stay normal even as cysts are destroying tissue, volume measurements by MRI or ultrasound can detect trouble years before blood work does.²⁰

The drug tolvaptan, which blocks the vasopressin V2 receptor and thereby reduces the cyclic AMP signal driving cyst expansion, became the first disease-modifying therapy for ADPKD. In the landmark TEMPO 3:4 trial, patients on tolvaptan saw their kidneys grow at about 2.8% per year versus 5.5% per year in the placebo group over three years, and they experienced fewer episodes of worsening kidney function and kidney pain.²¹ The drug does not cure the disease, and it comes with significant side effects, particularly the need to drink large amounts of water and urinate frequently because of how it works on the kidneys. Liver enzyme elevations also require monitoring. Still, it marked a turning point in management, and a European consensus statement has since laid out recommendations for identifying which patients are most likely to benefit.²²

Beyond medication, dietary and lifestyle strategies are recommended to help slow progression. Patients are generally advised to maintain an ideal body weight, drink plenty of fluids, keep sodium intake low, and limit concentrated sweets.²³ High fluid intake helps suppress vasopressin, the same hormone that tolvaptan blocks pharmacologically, making water an inexpensive and accessible complement to drug therapy.

Beyond the Kidneys in ADPKD

ADPKD is a systemic condition, not strictly a kidney disease. The same genetic defects that cause kidney cysts also affect other organs. Liver cysts are the most common extra-kidney finding, present in an estimated 94% of patients. Cysts in the seminal vesicles (about 40% of affected men), pancreas (around 9%), and the membranes surrounding the brain (about 8%) have also been documented. Connective-tissue abnormalities round out the picture: roughly a quarter of patients have mitral valve prolapse, about 8% have intracranial aneurysms, and around 10% develop abdominal hernias.²⁴ The intracranial aneurysm figure is particularly important because rupture can be life-threatening; screening with MRI angiography is often recommended for ADPKD patients who have a family history of brain aneurysms or hemorrhagic stroke.

Autosomal Recessive Polycystic Kidney Disease

The recessive form, ARPKD, is far rarer, occurring in roughly 1 in 20,000 live births. It is caused by mutations in a different gene, PKHD1, which encodes a protein called fibrocystin.²⁵ Unlike ADPKD, where cysts bud off and expand individually, ARPKD involves a distinctive widening of the collecting ducts throughout the kidney, giving the organs a spongy appearance. The liver is almost always affected as well, developing congenital hepatic fibrosis that can lead to portal hypertension and its complications.²⁶

ARPKD presents a broad clinical spectrum. The most severe cases are detected before birth or in the newborn period, sometimes with kidneys so enlarged they compress the developing lungs. Milder forms may not come to attention until childhood or even adolescence, when liver complications become the dominant problem. Because both parents must carry a copy of the mutated gene (and carriers are symptom-free), the diagnosis often comes as a complete surprise to families with no known history of kidney disease.

Acquired Cystic Kidney Disease

People with longstanding kidney failure, especially those on dialysis, can develop cysts in kidneys that were previously normal. This condition, called acquired cystic kidney disease, grows more common the longer a person has been on dialysis.²⁷ A compilation of data from multiple studies found that about a third of patients on maintenance hemodialysis develop it, and around 4% of those cases are complicated by kidney cancer.²⁸ For this reason, dialysis patients are sometimes screened periodically with imaging even though their kidneys are no longer functioning well.

Other Genetic Conditions With Kidney Cysts

Several hereditary syndromes include kidney cysts as part of a broader pattern of abnormalities. Tuberous sclerosis complex, caused by mutations in the TSC1 or TSC2 genes, produces fatty kidney tumors called angiomyolipomas alongside renal cysts.²⁹ Von Hippel-Lindau syndrome is another inherited condition where cystic kidney lesions appear, but in this case they carry a meaningful risk of developing into renal cell carcinoma.³⁰ Multicystic dysplastic kidney, meanwhile, is a developmental anomaly typically detected prenatally; the affected kidney is nonfunctional from the start and often shrinks over time. Most cases are unilateral and isolated, and the prognosis depends largely on whether the other kidney and the rest of the urinary tract are normal.³¹

What ties these disparate conditions together is that the word “cyst” on a radiology report does not, by itself, tell you which category you’re in. Context matters enormously: a single cyst in a 65-year-old with no family history of kidney disease is almost certainly simple and benign. Multiple bilateral cysts in a 30-year-old with an affected parent likely signals ADPKD. Cysts alongside fatty kidney tumors in a young patient raise suspicion for tuberous sclerosis. Radiologists and nephrologists piece together the number of cysts, their appearance, the patient’s age, family history, and any extrarenal findings to arrive at the right diagnosis.

Kidney Transplant Outcomes in PKD

For ADPKD patients whose kidneys eventually fail, transplantation is the preferred treatment when possible, and the outcomes are encouraging. A meta-analysis found that transplant recipients with PKD had better one-year survival and better ten-year graft survival compared with transplant recipients who had kidney failure from other causes.³² A separate single-center study also found lower risks of graft failure and death in the PKD group.³³ The likely explanation is that PKD patients tend to be otherwise relatively healthy compared with people whose kidneys failed from diabetes or severe vascular disease. One caution: PKD recipients do appear to have a higher rate of post-transplant diabetes, so monitoring for that after surgery is standard practice.³⁴

Living With Kidney Cysts and Mental Health

For people with simple cysts, the psychological burden is usually minimal once they learn the cyst is harmless. For those with ADPKD, the picture is more complicated. The disease is progressive and incurable, and the knowledge that kidney function may decline over decades creates a particular kind of chronic stress. Studies have found high rates of depression and anxiety in ADPKD patients, with one finding depression in about 60% of those surveyed.³⁵ Quality of life tends to decline as the stage of kidney disease advances, and anxiety and depression rise in parallel.³⁶

The uncertainty of the timeline plays a role here. Unlike many chronic conditions where you can broadly predict the course, ADPKD’s progression varies even within the same family. One sibling with the same mutation may reach kidney failure in their fifties while another retains reasonable function into their seventies. Genetic testing can identify which gene is affected and give a rough sense of severity, and kidney volume measurements can refine the prognosis further, but there is still no way to predict an individual’s trajectory with precision. For patients managing that uncertainty, connecting with support communities and proactively addressing mood symptoms can make a real difference in how the condition feels day to day, even when the kidney numbers have not changed.